165 related articles for article (PubMed ID: 11426529)
1. Cost-Effectiveness of interferon alfa-2b added to chemotherapy for high-tumor-burden follicular non-Hodgkin's lymphoma.
Wirt DP; Giles FJ; Oken MM; Solal-Celigny P; Beck JR
Leuk Lymphoma; 2001 Feb; 40(5-6):565-79. PubMed ID: 11426529
[TBL] [Abstract][Full Text] [Related]
2. Quality-of-life-adjusted survival analysis of interferon alfa-2b treatment for advanced follicular lymphoma: an aid to clinical decision making.
Cole BF; Solal-Céligny P; Gelber RD; Lepage E; Gisselbrecht C; Reyes F; Sebban C; Sugano D; Tendler C; Goldhirsch A
J Clin Oncol; 1998 Jul; 16(7):2339-44. PubMed ID: 9667248
[TBL] [Abstract][Full Text] [Related]
3. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte.
Solal-Celigny P; Lepage E; Brousse N; Reyes F; Haioun C; Leporrier M; Peuchmaur M; Bosly A; Parlier Y; Brice P
N Engl J Med; 1993 Nov; 329(22):1608-14. PubMed ID: 8232429
[TBL] [Abstract][Full Text] [Related]
4. Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial.
Solal-Céligny P; Lepage E; Brousse N; Tendler CL; Brice P; Haïoun C; Gabarre J; Pignon B; Tertian G; Bouabdallah R; Rossi JF; Doyen C; Coiffier B
J Clin Oncol; 1998 Jul; 16(7):2332-8. PubMed ID: 9667247
[TBL] [Abstract][Full Text] [Related]
5. An evaluation of the cost-effectiveness of rituximab in combination with chemotherapy for the first-line treatment of follicular non-Hodgkin's lymphoma in the UK.
Ray JA; Carr E; Lewis G; Marcus R
Value Health; 2010; 13(4):346-57. PubMed ID: 20070643
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of fludarabine/mitoxantrone/dexamethasone alternating with CHOP in bulky follicular non-Hodgkin's lymphoma.
Wilder DD; Ogden JL; Jain VK
Clin Lymphoma; 2002 Mar; 2(4):229-37. PubMed ID: 11970762
[TBL] [Abstract][Full Text] [Related]
7. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
8. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA).
Sebban C; Mounier N; Brousse N; Belanger C; Brice P; Haioun C; Tilly H; Feugier P; Bouabdallah R; Doyen C; Salles G; Coiffier B
Blood; 2006 Oct; 108(8):2540-4. PubMed ID: 16835383
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of interferon alfa in chronic myelogenous leukemia.
Liberato NL; Quaglini S; Barosi G
J Clin Oncol; 1997 Jul; 15(7):2673-82. PubMed ID: 9215840
[TBL] [Abstract][Full Text] [Related]
10. Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.
Papaioannou D; Rafia R; Rathbone J; Stevenson M; Buckley Woods H; Stevens J
Health Technol Assess; 2012; 16(37):1-253, iii-iv. PubMed ID: 23021127
[TBL] [Abstract][Full Text] [Related]
11. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte.
Brice P; Bastion Y; Lepage E; Brousse N; Haïoun C; Moreau P; Straetmans N; Tilly H; Tabah I; Solal-Céligny P
J Clin Oncol; 1997 Mar; 15(3):1110-7. PubMed ID: 9060552
[TBL] [Abstract][Full Text] [Related]
12. Rituximab for the first-line treatment of stage III/IV follicular non-Hodgkin's lymphoma.
Dundar Y; Bagust A; Hounsome J; McLeod C; Boland A; Davis H; Walley T; Dickson R
Health Technol Assess; 2009 Jun; 13 Suppl 1():23-8. PubMed ID: 19567210
[TBL] [Abstract][Full Text] [Related]
13. Cytarabine added to interferon improves the cost-effectiveness of initial therapy for patients with early chronic phase chronic myelogenous leukemia.
Beck JR; Guilhot J; Giles FJ; Aoki N; Wirt DP; Guilhot F
Leuk Lymphoma; 2001 Mar; 41(1-2):117-24. PubMed ID: 11342363
[TBL] [Abstract][Full Text] [Related]
14. Fludarabine alone compared to CHVP plus interferon in elderly patients with follicular lymphoma and adverse prognostic parameters: a GELA study. Groupe d'Etudes des Lymphomes de l'Adulte.
Coiffier B; Neidhardt-Bérard EM; Tilly H; Belanger C; Bouabdallah R; Haioun C; Brice P; Péaud PY; Pico JL; Janvier M; Solal-Celigny P; Brousse N
Ann Oncol; 1999 Oct; 10(10):1191-7. PubMed ID: 10586336
[TBL] [Abstract][Full Text] [Related]
15. [Economic analysis of rituximab in combination with cyclophosphamide, vincristine and prednisolone in the treatment of patients with advanced follicular lymphoma in Portugal].
Braga P; Carvalho S; Gomes M; Guerra L; Lúcio P; Marques H; Negreiro F; Pereira C; Silva C; Teixeira A
Acta Med Port; 2010; 23(6):1025-34. PubMed ID: 21627880
[TBL] [Abstract][Full Text] [Related]
16. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study.
Salles G; Mounier N; de Guibert S; Morschhauser F; Doyen C; Rossi JF; Haioun C; Brice P; Mahé B; Bouabdallah R; Audhuy B; Ferme C; Dartigeas C; Feugier P; Sebban C; Xerri L; Foussard C
Blood; 2008 Dec; 112(13):4824-31. PubMed ID: 18799723
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d'Etude des Lymphomes de l'Adulte (GELA) and Groupe Ouest Est des Leucémies et Autres Maladies du Sang (GOELAMS).
Morschhauser F; Mounier N; Sebban C; Brice P; Solal-Celigny P; Tilly H; Feugier P; Fermé C; Copin MC; Lamy T
Cancer; 2010 Sep; 116(18):4299-308. PubMed ID: 20549824
[TBL] [Abstract][Full Text] [Related]
18. Interferon-alpha for maintenance of follicular lymphoma.
Baldo P; Rupolo M; Compagnoni A; Lazzarini R; Bearz A; Cannizzaro R; Spazzapan S; Truccolo I; Moja L
Cochrane Database Syst Rev; 2010 Jan; (1):CD004629. PubMed ID: 20091564
[TBL] [Abstract][Full Text] [Related]
19. Treatment of follicular non-Hodgkin's lymphoma with or without rituximab: cost-effectiveness and value of information based on a 5-year follow-up.
Soini EJO; Martikainen JA; Nousiainen T
Ann Oncol; 2011 May; 22(5):1189-1197. PubMed ID: 21135053
[TBL] [Abstract][Full Text] [Related]
20. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
Shepherd J; Brodin H; Cave C; Waugh N; Price A; Gabbay J
Health Technol Assess; 2004 Oct; 8(39):iii-iv, 1-125. PubMed ID: 15461877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]